Launch of new policy for treatment of Covid-19 with Neutralising monoclonal antibodies (nMABs)
Written by AlisonFreemantle on Thursday 9th December 2021
This is for information only, to aid you with any questions from patients
On the 8th December the government announced the Interim Clinical Commissioning Policy on Neutralising monoclonal antibodies or antivirals for non-hospitalised patients with COVID-19. Effective from: 16 December 2021.
Neutralising monoclonal antibodies (nMABs) are recommended to be available as a treatment option through routine commissioning for non-hospitalised adults and children (aged 12 years and above) with COVID-19 treated in accordance with a defined criterion. Where treatment with an nMAB is contraindicated or not possible, eligible patients may be offered an antiviral as an alternative.
A national study called PANORAMIC, run by the University of Oxford in close collaboration with GP hubs, has now launched and is recruiting around 10,000 UK patients at risk of serious illness from COVID-19 to have the opportunity to take the treatment molnupiravir at home after receiving a positive PCR test.
Those patients at highest risk who test positive for the virus e.g. people who are immunocompromised, cancer patients or those with Down’s syndrome – will also be able to access either molnupiravir or the novel monoclonal antibody Ronapreve outside of the study from 16 December 2021.
Further details on the policy, study and drugs are available here: